The global pet cancer therapeutics market is expected to grow at a CAGR of 7.2% from 2021 to 2030. The growth of the market can be attributed to the increasing number of pet owners, rising awareness about pet health, and increasing disposable income in developing countries.
Chemotherapy drugs are used for treating cancer in pets and are expected to account for the largest share of the global market during the forecast period. Chemotherapy drugs are administered intravenously or orally and work by killing rapidly dividing cells that cause cancerous tumors. Targeted therapy is another type of drug which targets specific proteins on tumor cells that help them grow or spread, thereby preventing their growth or spreading. Combination therapy is a combination of two or more types of drugs which work together to kill tumor cells faster than either drug alone would have done on its own. Immunotherapy is a type that stimulates an immune response against cancerous cells by using antibodies, cytokines, and other substances that activate immune system components such as T-cells and natural killer (NK) cells.
-The global market for pet cancer therapeutics is expected to grow at a CAGR of 7.2% from 2017 to 2022.
-The global pet cancer therapeutics market is expected to reach USD 3,890 million by 2022, growing at a CAGR of 7.2% from 2017 to 2022.
-Increasing awareness about the benefits of pet care and treatment are driving the growth of this market The increasing number of pets in households across the world is also driving this growth as more people are becoming aware about the benefits that pets provide in terms of companionship and emotional support.
Industry Growth Insights published a new data on “Pet Cancer Therapeutics Market”. The research report is titled “Pet Cancer Therapeutics Market research by Types (Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy), By Applications (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others), By Players/Companies Aratana Therapeutics, Inc, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc, VetDC, Inc, Karyopharm Therapeutics, Inc, Rhizen Pharmaceutical SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, Zoetis”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pet Cancer Therapeutics Market Research Report
By Type
Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy
By Application
Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others
By Companies
Aratana Therapeutics, Inc, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc, VetDC, Inc, Karyopharm Therapeutics, Inc, Rhizen Pharmaceutical SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, Zoetis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Pet Cancer Therapeutics Market Report Segments:
The global Pet Cancer Therapeutics market is segmented on the basis of:
Types
Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aratana Therapeutics, Inc
- AB Science
- Boehringer Ingelheim International GmbH
- Zenoaq
- Morphogenesis, Inc
- VetDC, Inc
- Karyopharm Therapeutics, Inc
- Rhizen Pharmaceutical SA
- Regeneus Ltd.
- Oasmia Pharmaceuticals AB
- Zoetis
Highlights of The Pet Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary
- Squamous Cell Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pet Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pet cancer therapeutics is a new and rapidly growing field of veterinary medicine that focuses on the development of treatments for pet cancers. These treatments may include chemotherapy, radiation therapy, and surgery.
Some of the major players in the pet cancer therapeutics market are Aratana Therapeutics, Inc, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc, VetDC, Inc, Karyopharm Therapeutics, Inc, Rhizen Pharmaceutical SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, Zoetis.
The pet cancer therapeutics market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pet Cancer Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pet Cancer Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pet Cancer Therapeutics Market - Supply Chain
4.5. Global Pet Cancer Therapeutics Market Forecast
4.5.1. Pet Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pet Cancer Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pet Cancer Therapeutics Market Absolute $ Opportunity
5. Global Pet Cancer Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pet Cancer Therapeutics Market Size and Volume Forecast by Type
5.3.1. Chemotherapy
5.3.2. Targeted Therapy
5.3.3. Combination Therapy
5.3.4. Immunotherapy
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pet Cancer Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pet Cancer Therapeutics Market Size and Volume Forecast by Application
6.3.1. Lymphoma
6.3.2. Mast Cell Cancer
6.3.3. Melanoma
6.3.4. Mammary
6.3.5. Squamous Cell Cancer
6.3.6. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pet Cancer Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pet Cancer Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pet Cancer Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pet Cancer Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pet Cancer Therapeutics Demand Share Forecast, 2019-2026
9. North America Pet Cancer Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pet Cancer Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pet Cancer Therapeutics Market Size and Volume Forecast by Application
9.4.1. Lymphoma
9.4.2. Mast Cell Cancer
9.4.3. Melanoma
9.4.4. Mammary
9.4.5. Squamous Cell Cancer
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pet Cancer Therapeutics Market Size and Volume Forecast by Type
9.7.1. Chemotherapy
9.7.2. Targeted Therapy
9.7.3. Combination Therapy
9.7.4. Immunotherapy
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pet Cancer Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Pet Cancer Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pet Cancer Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pet Cancer Therapeutics Market Size and Volume Forecast by Application
10.4.1. Lymphoma
10.4.2. Mast Cell Cancer
10.4.3. Melanoma
10.4.4. Mammary
10.4.5. Squamous Cell Cancer
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pet Cancer Therapeutics Market Size and Volume Forecast by Type
10.7.1. Chemotherapy
10.7.2. Targeted Therapy
10.7.3. Combination Therapy
10.7.4. Immunotherapy
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pet Cancer Therapeutics Demand Share Forecast, 2019-2026
11. Europe Pet Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pet Cancer Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pet Cancer Therapeutics Market Size and Volume Forecast by Application
11.4.1. Lymphoma
11.4.2. Mast Cell Cancer
11.4.3. Melanoma
11.4.4. Mammary
11.4.5. Squamous Cell Cancer
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pet Cancer Therapeutics Market Size and Volume Forecast by Type
11.7.1. Chemotherapy
11.7.2. Targeted Therapy
11.7.3. Combination Therapy
11.7.4. Immunotherapy
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pet Cancer Therapeutics Demand Share, 2019-2026
12. Asia Pacific Pet Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pet Cancer Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pet Cancer Therapeutics Market Size and Volume Forecast by Application
12.4.1. Lymphoma
12.4.2. Mast Cell Cancer
12.4.3. Melanoma
12.4.4. Mammary
12.4.5. Squamous Cell Cancer
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pet Cancer Therapeutics Market Size and Volume Forecast by Type
12.7.1. Chemotherapy
12.7.2. Targeted Therapy
12.7.3. Combination Therapy
12.7.4. Immunotherapy
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pet Cancer Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Pet Cancer Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pet Cancer Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pet Cancer Therapeutics Market Size and Volume Forecast by Application
13.4.1. Lymphoma
13.4.2. Mast Cell Cancer
13.4.3. Melanoma
13.4.4. Mammary
13.4.5. Squamous Cell Cancer
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pet Cancer Therapeutics Market Size and Volume Forecast by Type
13.7.1. Chemotherapy
13.7.2. Targeted Therapy
13.7.3. Combination Therapy
13.7.4. Immunotherapy
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pet Cancer Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pet Cancer Therapeutics Market: Market Share Analysis
14.2. Pet Cancer Therapeutics Distributors and Customers
14.3. Pet Cancer Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aratana Therapeutics, Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AB Science
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim International GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Zenoaq
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Morphogenesis, Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. VetDC, Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Karyopharm Therapeutics, Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Rhizen Pharmaceutical SA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Regeneus Ltd.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Oasmia Pharmaceuticals AB
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Zoetis
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
